MedTrace Logo

Hemostatic Effects of VELCADE®* Treatment in Multiple Myeloma Patients

NCT01720043 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2017-09-05

Study results available
· View outcomes & findings →

Summary

To evaluate the effect of VELCADE on platelet aggregation at baseline, 24 hours and 48 hours after infusion in patients with multiple myeloma

Conditions

Interventions

DRUG

Velcade

Single dose of Velcade (1.0-1.3 mg/m2 dose)

Sponsors & Collaborators

Principal Investigators

  • Tibor Kovacsovics, MD · Huntsman Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2015-04-30
Completion
2017-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01720043 on ClinicalTrials.gov